Shaghik

Fond of immuno-oncology, NK cell, KIR/HLA/Peptide, passionately curious, a dancer who dance with music in her soul
⁦

[Shaghik @ShaghikBarani]

#KIR #Diversity #human #migration @FrontImmunol @rajalingam1963 Allele Frequency Net Database (#AFND)

[inmunoes @inmunoes]

Global patterns of KIR genotype diversity reflect human migration and regional differences https://t.co/n624GRVEDY #FrontImmunol

[Waggoner Lab @LabWaggoner]

Circulating tumor-reactive KIR+CD8+ T cells suppress anti-tumor immunity in patients with melanoma
https://t.co/kkbdrspmqO
@DavidHaflerMD @NatImmunol @Benjamin_Y_Lu

[Katy Rezvani, M.D., Ph.D @lab_rezvani]

Deep gratitude to MDACC leadership and Board of Visitors, my incredible team, our collaborators, and everyone who joined us for today’s launch of the Institute for Cell Therapy Discovery and Innovation. Your support and belief in our vision inspire us to push the boundaries of cell therapy research. Read more: https://t.co/XMxOGxrVkU #EndCancer @MDAndersonNews #CellTherapy #Institute

[Nicholas Huntington @Dr_Nick_Bikes]

NK cell sesh #STIC2024 Genome-wide CRISPR screens in NK cells discovers the IL-15R regulome, >10 ph I NK cell therapy trials & aNKG2A mAb in Ph III. We've come a long way in 5 years @lab_rezvani @EricVivier1 @oNKo_innate @InnatePharma @MDAndersonNews

[May Daher @may_daher]

What an amazing culmination of so many years of hard work, dedication, passion and innovation! Congratulations @lab_rezvani on the launch of the Institute for Cell Therapy Discovery & Innovation. I am so proud and humbled to be part of the team that made this dream come true 💕 @MDAndersonNews #celltherapy #cancer #autoimmunity

[Moffitt Cancer Center @MoffittNews]

At #CellCoast24, @DrFredLocke joins @DrNatashaKekre from @uOttawa and @romeerizwan from @DanaFarber to discuss the latest in point of care for CAR-T manufacturing and NK cellular therapies.

[The Nobel Prize @NobelPrize]

”My mother told me, 'Kati, you know, next week they are announcing who will be awarded to Nobel Prize. I will listen, you might get it, they might say your name!' I told her, 'Don't worry'.”

Katalin Karikó speaks about her journey to the #NobelPrize: https://t.co/V7NMdiHzeS

[Waggoner Lab @LabWaggoner]

CD8+ T-cell responses towards conserved influenza B virus epitopes across anatomical sites and age @KatherineKedz @RossjohnLab @Jamie_Rossjohn @tony_purcell8 @CvandeSandt @Tejas_the_Tcell @patricia_illing
https://t.co/srwUKUNLL2

[Waggoner Lab @LabWaggoner]

Spatial analysis reveals combinative role for NK and CD8 T cells in antitumor immunity despite profound MHC class I loss in non-small cell lung cancer @RemziyeErdogan5 @sepiddsh
https://t.co/iKEaQWPrOb

[Eric Vivier @EricVivier1]

I am excited to share this piece published in Nature and co-authored with @L. Rebuffet, @E. Narni-Mancinelli, @S. Cornen, @R. Igarashi and @V. Fantin, exploring therapeutic strategies focused on NK cells and the role of these cells in cancer immunity. https://t.co/dxRDWpnN6j

[Nature Medicine @NatureMedicine]

#Allogeneic CD19-specific #CAR-#NKcells were safe & efficacious in patients with CD19+ hematologic malignancies, with distinct cord blood features associated with response @lab_rezvani @Yl668Li @rftbsr9 @HindRafei @may_daher #lymphoma #leukemia
https://t.co/imWhfIGhfG

[Eric Vivier @EricVivier1]

New immune cell engagers for cancer immunotherapy | Nature Reviews Immunology https://t.co/clGVIhJ4KW

[Waggoner Lab @LabWaggoner]

Phase 1/2 trial of cord blood CD19-CAR-NK cells in 37 patients with CD19+ B cell malignancies. Promising 1 year progression free + overall response rates of 32% and 68%. Donor selection is crucial: units preserved w/in 24hrs & w/ low red cell content were superior @lab_rezvani

[Waggoner Lab @LabWaggoner]

IL-15 administration prevented loss of function and improved tumor control, generating intratumoral NK cells with both tissue-residency characteristics and enhanced effector function @LabWithers @ClatworthyLab
https://t.co/G5gzrsaRKT

[Waggoner Lab @LabWaggoner]

Manufacturing of primary CAR-NK cells in an automated system for the treatment of acute myeloid leukemia
https://t.co/7nqkkwDtsD

[Waggoner Lab @LabWaggoner]

IKAROS & AIOLOS are important regulators of apoptosis, cytokine responsiveness and AP-1 transcriptional activity in NK cell development
@Dr_Nick_Bikes @AlinePfefferle @SebScheer @S_Foroutan @HSudholz Wilford Goh @NatImmunol https://t.co/aIbLebGUgZ

[Waggoner Lab @LabWaggoner]

Indigenous Australian genomes show deep structure and rich novel variation @Nature @seasteal #Leslie
https://t.co/GCI5RiUxIP

[Waggoner Lab @LabWaggoner]

In situ vaccination approach that combines radiation and intratumoral injection of a tumor-specific antibody and IL-2 (3xTx) elicits CD8+ T cell immunity supported by NK cell-mediated regulatory T cell antagonism in non-targeted tumors @CellReports
https://t.co/7E4GtU3wVN

[May Daher @may_daher]

Stunning and brilliant! A stellar lecture by @lab_rezvani to showcase the groundbreaking research and very promising clinical responses in patients treated with #CARNK cells. Katy -may your star keep shining as we carry on our mission to make cancer history @MDAndersonNews #ASH

[immunoboys, MD/PhD @immunoboys]

The number of KIR-HLA interactions predict CD8 T cell lifespan in humans. In this @jclinicalinvest report comparing intra- and interindividual effects, Zhang et al show that indirect interactions prolong T cell life span independent of the KIR expression on single cells
(1/2)